NCT05676242CompletedPhase 3
A Phase III Extended Clinical Trial of Jaktinib Hydrochloride Tablets in the Treatment of Moderate and Severe Atopic Dermatitis
A Phase III Extended Clinical Trial of Long-term Safety and Efficacy of Jaktinib Hydrochloride Tablets in the Treatment of Moderate and Severe Atopic Dermatitis
Source: ClinicalTrials.gov · Last updated 3 Nov 2026
Brief summary (registry, in English)
To observe the safety and effectiveness of long-term use of jaktinib hydrochloride tablets in the treatment of moderate and severe atopic dermatitis
- Status (registry)
- Completed
- Phase (registry)
- Phase 3
- Study type
- Interventional
- Enrollment
- 207 (actual)
- First submitted
- 30 Dec 2022
- Start date
- 11 Jan 2023
- Primary completion date
- 12 Mar 2026
- Lead sponsor
- Suzhou Zelgen Biopharmaceuticals Co.,Ltd
- Diseases
- Atopic dermatitis (eczema)
- NCT number
- NCT05676242
What you commit to
- Study type: Interventional · Phase 3
- Participants enrolled: 207
- From 11 Jan 2023 to the primary completion date, 12 Mar 2026
- 2 sites in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Within 4 weeks before enrollment, there were any adverse events ≥ 3 levels related to the test drug that did not return to level 1 or normal;
Other
- The investigator thinks that the subject is not suitable for the trial.
Who the study is looking for
- The investigator thinks that the subject can continue to benefit from participating in the extension trial;
- Fully understand the extension trial and sign the informed consent form;
- Complete the ZGJAK025 trial for 16 weeks and have good compliance;
- It is expected that the time interval between the first administration and the last administration of ZGJAK025 trial for the subject should be ≤ 4 weeks;
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (2)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Peking University People's Hospital Coordinator of this site? Confirm its status | Beijing | China | Unknown status |
| Hospital for Skin Diseases, Institute of Dermatology, Chinese Academy of Medical Sciences, Peking Union Medical College Coordinator of this site? Confirm its status | Nanjin | China | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.